Celldex Therapeutics, Inc. (NasdaqCM: CLDX)
Health Care · Biotechnology · US
$41.40
+0.44% today · +88.0% 1Y
Celldex Therapeutics, Inc. (NasdaqCM: CLDX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $3.24B and employs 198 people.
Over the last twelve months the share price has gained 88.0%, trading between 20.37 and 45.14.
Tweenvest scores Celldex Therapeutics, Inc. across four factors: quality 28/100, growth 0/100. Its strongest factor is quality.
CLDX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $3.24B
- Revenue (TTM)
- $158.00K
- P/E
- —
- EPS
- -4.33
- Dividend yield
- —
- Beta (5Y)
- 0.84
- 52-week high
- $45.14
- 52-week low
- $20.37
- Avg volume (3M)
- —
- Shares outstanding
- 78.53M
- Employees
- 198
- Next earnings
- —
About Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc. is a biopharmaceutical company dedicated to developing antibody-based treatments, specifically monoclonal and bispecific antibodies, for a range of diseases. Their pipeline features therapeutic candidates aimed at both inflammatory conditions and various forms of cancer. Among their key clinical programs: CDX-0159 is a Phase I monoclonal antibody designed to bind to and inhibit the activity of the KIT receptor tyrosine kinase. CDX-1140 is a human agonist monoclonal antibody that targets CD40, a critical immune response activator found on immune cells such as dendritic cells, macrophages, and B cells, as well as on several cancer cell types. CDX-527 is a bispecific antibody that integrates Celldex's proprietary anti-PD-L1 and CD27 human antibodies. Its mechanism involves combining CD27 costimulation with blockade of the PD-L1/PD-1 pathway to prime and activate anti-tumor T-cell responses. The company has established several research collaborations and licensing agreements, including partnerships with the University of Southampton for developing human antibodies targeting CD27, Amgen Inc. for exclusive rights to CDX-301 and CD40 ligand, and Yale University. Incorporated in 1983, Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.
- ISIN
- US15117B2025
- Listed since
- May 15, 1986
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $266.00 | +0.08% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.45 | +0.05% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.74 | -0.02% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.00 | -0.15% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $832.63 | -0.11% |
| argenx SEENXTBR: ARGX | $64.17B | €909.60 | +3.46% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $157.49 | -0.84% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.